Drug Patent Expirations for the week of May 27, 2012

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
IONSYS	Incline Therap	fentanyl hydrochloride	6,317,629	Jun 2, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Top 75 pharmacy colleges in India

Institutions	Seats
Al-Ameen College of Pharmacy, Bangalore	60
Amity School of Pharmacy, Amity University, Noida	NA
Amrita School of Pharmacy, Kochi	60
AR College and GH Patel Instt of Pharmacy, Vallabh Vidyanagar	40
B.N.P.G.College of Pharmacy, Udaipur	60
Banaras Hindu University, Varanasi	25
Bharati Vidyapeeth University, Pune	100
Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai	60
Birla Instittue of Technology, Mesra	30
BK Mody Government Pharmacy College, Rajkot	30
Bombay College of Pharmacy, Mumbai	60
College of Pharmaceutical Science, Mohud, Berhampur	60
College of Pharmaceutical Science, Thiruvananthapuram	60
College of Pharmaceutical Sciences, Andhra University	NA
College of Pharmacy, IPS Academy, Indore	60
Delhi Institute of Pharmaceutical Sciences & Research, New Delhi	60
Department of Pharmacy, Annamalai University, Tamil Nadu	100
Department of Pharmaceutical Sciences, Dibrugarh	15
Department of Pharmaceutical Sci, RTMN University Nagpur	60
Department of Pharmacy Sciences, M.D University, Rohtak	60
Department of Pharmacy, BITS Pilani, Pilani	60
Department of Pharmacy, Lovely Institute of Tech, Phagwara	60
Department of Pharmacy, Madras Medical College	NA
Deptt. of Pharmaceutical Sciences, Dr. H.S Gour University, Sagar	60
Deptt. of Pharmaceutical Tech, Jadhavpur University	70
Deptt. of Pharmacy, MS University of Badora, Vadodra	40
Faculty of Pharmacy, Jamia Hamdard, New Delhi	60
GITAM Institute of Pharmacy, Vishakapatnam	60
Goa College of Pharmacy, Panaji, Goa	NA
Govt. College of Pharmacy, Bangalore	NA
Himalayan Pharmacy Institute Majhitar,Rangpo	NA
Indira College of Pharmacy, Pune	60
Institute of Chemical Tech. (I.C.T), University of Bombay, Mumbai	30
J.S.S. College of Pharmacy, Mysore	100
J.S.S. College of Pharmacy, Ooty	100
JVD College of Science and Technology, Vishakapatnam	40
K.L.E. Society's College of Pharmacy, Belgaum	100
K.M.Kundnani College of Pharmacy, Mumbai	60
KIET School of Pharmacy, Ghaziabad	60
KLES College of Pharmacy, Hubli	60
L. M. College of Pharmacy, Ahmedabad	90
M.M. College of Pharmacy, Mullana	60
M.S. Ramaiah College of Pharmacy , Bangalore	60
Manipal College of Pharmaceutical Sciences, Manipal	100
Mohamed Sathak A.J. College of Pharmacy, Chennai	60
Muzzaffarpur Institute of Technology, Muzaffarpur	15
National lnstitute of Pharmaceutical Education and Research (NIPER), Ahmedabad	NA
NIMS Institute of Pharmacy & NIMS College of Pharmacy, Jaipur	60
NIPER, Hajipur	NA
NIPER, Hyderabad	NA
NIPER, Kolkata	NA
NIPER, Mohali	NA
NIPER, Rai Bareli	NA
Nirma University – Institute of Pharmacy, Ahmedabad	60
NMIMS (Pharmacy Department), Mumbai	NA
NSHM College of Pharmaceutical Technology, Kolkata	60
PES College of Pharmacy, Bangalore	60
PRES Pravara Rural College of Pharmacy, Distt Ahmednagar	60
PSG College of Pharmacy, Coimbatore	60
Pune University (Pharmacy Department), Pune	NA
Punjabi University (Pharmacy Department), Patiala	60
S.R.M College of Pharmacy, Kattankulathur	100
Sagar Institute of Pharmaceutical Sciences, Sagar	60
Sagar Institute of Research & Technology-Pharmacy, Bhopal	60
School of Pharmacy, DAVV, Indore	60
SGS Institutes of Technology & Science, Indore	60
Singhad Technical Education Society, Pune	60
Sri Ramachandra College of Pharmacy, SRMC&RI, Chennai	60
University College of Pharm. Sci., Kakatiya University, Warangal	60
University College of Pharmaceutical Sciences, Warangal	NA
University Deptt. of Pharmaceutical Sci., Utkal University, Orissa	NA
University Institute of Pharmaceutical Sciences, Panjab University	NA
University Institute of Pharmaceutical Technology, Annamalai	60
VEL's College of Pharmacy, Chennai	100
Vinayaka Mission's College of Pharmacy, Salem

India's Best Pharmacy Colleges

College	Rank
NIPER, Mohali	1
University Institute of Pharmaceutical Sciences, Panjab University	2
Manipal College of Pharmaceutical Sciences, Manipal	3
Bombay College of Pharmacy, Kalina, Mumbai	4
JSS College of Pharmacy, Ooty	5
University College of Pharmaceutical Sci, Kakatiya University, Warangal	6
L.M. College of Pharmacy, Ahmedabad	6
Department of Pharmaceutical Sci, Dr. H.S. Gour University, Sagar, MP	6
Institute of Chemical Technology (ICT), Mumbai (erstwile UDCT)	9
Pharmacy Group, BITS, Pilani	10
Department of Pharmaceutical Engineering, IT-BHU	10
Department of Pharmaceutical Sciences, BIT Mesra, Ranchi	12
JSS College of Pharmacy, Mysore	13
Delhi Instt. of Pharmaceutical Sciences & Research, Delhi	14
Al-Ameen College of Pharmacy, Bangalore	15
Poona College of Pharmacy, Bharati Vidyapeeth, Pune	15
Dept. of Pharmacy, MS University, Baroda	15
Dept. of Pharmaceutical Sciences, Nagpur University	15
College of Pharmaceutical Sciences, Andhra University	19
School of Pharmacy, Devi Ahilya University, Indore	19
Goa College of Pharmacy, Panaji, Goa	21
Faculty of Pharmacy, Jamia Hamdard, New Delhi	21
KLEU's Collee of Pharmacy, Belgaum, Karnataka	21
Department of Pharmacy, Madras Medical College	21
Department of Pharmaceutical Technology, Jadavpur University	25
PSG College of Pharmacy, Coimbatore	25
Govt. College of Pharmacy, Bangalore	25

Indian Pharma Expo 2012

CALL FOR PARTICIPATION

Indian Pharma Expo 2012 is the perfect solution to meet the needs of the rapidly growing Indian pharma industry; to be able to network under one roof. UBM Medica by its unparralled multichannel reach to the right and relevant audience through its leading brands like CIMS, IDR & cimsasia.com is in the best position to provide the ideal platform to connect, communicate and collaborate with each and every segment of Indian pharma industry. Each part of the Indian Pharma Expo 2012 is well researched, diligently planned and flawlessly executed to deliver you a high quality experience that exceeds expectation. OBJECTIVES • To build brands • To expand geographically through Franchisee operations • To launch new products more aggressively • To reach more number of customers • To enhance brand image • To analyze the market potential for various products existing in the global markets • To analyze the competition scenario • To tap the market potential

SPONSORS & EXHIBITOR'S PROFILE

The event is targeted for the following: • Pharmaceutical company marketing/Purchase /Export professionals across India & Abroad • Manufacturers of : Pharmaceutical Formulation; API-Active Pharma Ingredients.(Bulk Drugs); Pharmaceutical Machinery;Ayurvedic / Herbal Products; NutraceuticalProduct / Dietary Supplements; Cosmetics Products; Veterinary Drug; Medical &Disposal; Excipients / Food Additives. /Natural Extracts; Flavors & Fragrances;Pharmaceutical Packaging material andmachinery; Diagnostic Reagents; BioPharmaceuticals; Laboratory equipment /Lab. Chemical • PCD / TPM • Companies offering franchise • R & D / Testing Labs • Analytical Services • Contract Research Organizations (CRO) • Association / Media / Publications • Consultant • Pharma Ancillary/ Utility/TechnologySuppliers

WHO SHOULD ATTEND?

• Pharmaceutical company marketing / Purchase /Export professionals across India & Abroad • Merchant Exporters • Contract Manufacturers • Individuals/companies seeking franchise • Generic & OTC manufacturer & wholesalers • Government supplier / liaison agents • Indenting agent • Pharmaceutical Machinery manufacturers & traders • Packaging Material Companies • Research Institutions • Biotechnology Company • Regulators & Policy Makers • Govt. Organizations & PSUs • Industry Associations & the Key Members • Diplomats, Foreign Dignitaries, Commercial Attaches • VVIPs from the Central & State Government

For further enquiries, please contact: Surobhi Event Coordinator Tel: 0124 4636516 Mobile: 9899609646 E-mail: surobhi.chakravarty@ubm.com Gaurav Samajdar Event Coordinator Tel: 0124 4636513 Mobile: 9871497362 E-mail: gaurav.samajdar@ubm.com

About this e-mail: You are receiving this message as a service from UBM Medica. UBM Medica respects your time and privacy. If you are not interested in receiving future e-mails from us, click hereto unsubscribe. To manage your MIMS.com profile and preferences, follow this link. Copyright © 2012 UBM Medica | 611 - 617, Sagar Tech Plaza A, Saki Naka, Andheri Kurla Road, Andheri East, Mumbai 400-072, Maharashtra, India.

Intake of Calcium Supplements Double Heart Attack Risk

Researchers have warned to take calcium supplements with caution as it could increase the risk of heart attack. 

Furthermore, boosting overall calcium intake from dietary sources confers no significant advantage in terms of staving off heart disease and stroke, the findings indicate. 

Previous research has linked higher calcium intake with a lowered risk of high blood pressure, obesity, and type 2 diabetes, all of which are risk factors for heart disease and stroke. 

And calcium supplements are commonly recommended to elderly people and women who have gone through the menopause to prevent bone thinning. 

The authors base their findings on almost 24,000 participants of one of the German arms of the European Prospective Investigation into Cancer and Nutrition (EPIC) study in Heidelberg. 

All the participants were aged between 35 and 64 when they joined the study in 1994-8. 

Normal diet for the preceding 12 months was assessed using food frequency questionnaires and they were quizzed about whether they regularly took vitamin or mineral supplements. 

Their health was tracked for an average of 11 years, during which time 354 heart attacks, 260 strokes, and 267 associated deaths occurred. 

After taking account of factors likely to influence the results, those whose diets included a moderate amount (820 mg daily) of calcium from all sources, including supplements, had a 31% lower risk of having a heart attack than those in the bottom 25% of calcium intake. 

But those with an intake of more than 1100 mg daily did not have a significantly lower risk.There was no evidence that any level of calcium intake either protected against or increased the risk of stroke, which backs up the findings of other research, say the authors. 

But when the analysis looked at vitamin/mineral supplements, it found that those who took calcium supplements regularly were 86% more likely to have a heart attack than those who didn't use any supplements. 

And this risk increased further among those who used only calcium supplements. They were more than twice as likely to have a heart attack as those who didn't take any supplements. 

The authors conclude: "This study suggests that increasing calcium intake from diet might not confer significant cardiovascular benefits, while calcium supplements, which might raise [heart attack] risk, should be taken with caution." 

In an accompanying editorial, Professors Ian Reid and Mark Bolland from the Faculty of Medical and Health Science at the University of Auckland in New Zealand, say that the safety of calcium supplements "is now coming under increasing scrutiny." 

They point to previous research, showing a link between these supplements and kidney stones, and gut and abdominal symptoms, and note that while trial evidence suggests that calcium supplements cut levels of cardiovascular risk factors, this doesn't actually translate into fewer heart attacks and strokes. 

They also suggest that many women taking calcium supplements to ward off brittle bones are already healthier than those who don't, and that the overall protective effect is modest—in the order of just 10%. 

The evidence that dietary calcium is helpful while calcium supplements are not can be explained by the fact that dietary calcium is taken in small amounts, spread throughout the day, so is absorbed slowly, they say. 

Supplements, on the other hand, cause calcium levels in the blood to soar above the normal range, and it is this flooding effect which might ultimately be harmful, they suggest. 

"Calcium supplements have been widely embraced by doctors and the public, on the grounds that they are a natural and therefore safe way of preventing osteoporotic fractures," they write. 

"It is now becoming clear that taking this micronutrient in one or two daily [doses] is not natural, in that it does not reproduce the same metabolic effects as calcium in food," they say. 

Given that it is neither safe nor effective, boosting calcium intake from supplements should be discouraged, they contend. 

And they conclude: "We should return to seeing calcium as an important component of a balanced diet, and not as a low cost panacea to the universal problem of postmenopausal bone loss." 

Source-Eurekalert

 

Dramatic blood sugar control with gastric surgery

Gastric surgery controlled blood sugar better than intensive medical therapy among obese type 2 diabetics, according to the STAMPEDE trial, the results of which were presented recently at the recent 61st Annual Scientific Sessions of the American College of Cardiology meeting in Chicago, Illinois, US.

Patients who underwent Roux-en-Y gastric bypass surgery or sleeve gastrectomy achieved HbA1c control below 6 percent within a year in 42 percent (P=0.002) and 37 percent of cases (P=0.008), respectively, compared with 12 percent who received intensive medical therapy alone. [N Engl J Med 2012 Mar 26. Epub ahead of print]

“Despite improvements in pharmacotherapy, fewer than 50 percent of patients with moderate-to-severe type 2 diabetes actually achieve and maintain therapeutic thresholds, particularly for glycemic control,” said researchers from the Cleveland Clinic in Ohio, US, Veterans Affairs Boston Healthcare System and Brigham and Women’s Hospital in Boston, Massachusetts, US.

“Observational studies have suggested that bariatric or metabolic surgery can rapidly improve glycemic control...”

The trial randomized 150 obese patients (mean age 49 years, mean body mass index 36 kg/m2, mean HbA1c 9.2 percent) with uncontrolled type 2 diabetes to receive intensive medical therapy alone, medical therapy plus Roux-en-Y gastric bypass surgery or medical therapy plus sleeve gastrectomy.

Intense medical therapy followed the guidelines of the American Diabetes Association and included lifestyle counselling, weight management, and drug therapy.

Patients randomized to surgery experienced significantly more weight loss compared with those receiving medical therapy after 12 months (-29.5 kg gastric bypass, -25.1 kg sleeve gastrectomy, -5.4 kg medical therapy, P<0.001 for both) and lead author Dr. Philip Schauer, of the Cleveland Clinic, said this, more than anything else, was the likely driver for glycemic control.

Mean HbA1c was 6.4 percent in the gastric bypass group (P<0.001), 6.6 percent in the sleeve gastrectomy group (P=0.003) and 7.5 percent among patients receiving medical therapy.

Patients who underwent surgery also significantly reduced or halted use of glucose control and cardiovascular medications.

“Reductions in the use of diabetes medications occurred before achievement of maximal weight loss, which supports the concept that the mechanisms of improvement in diabetes involve physiologic effects in addition to weight loss...” the researchers said.

No deaths or life threatening complications occurred although four patients required a second surgery for complications.

In an accompanying comment, Dr. Paul Zimmet, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia, and Dr. K. George M. M. Alberti, Kings College Hospital, London, England, said surgery would not be the “universal panacea” for obese patients with type 2 diabetes and pointed out that the study duration was only 1 year and that surgery has inherent hazards. [N Engl J Med 2012 Mar 26. Epub ahead of print]

“There is also the problem of ‘remission’ versus ‘cure,’” they said. “Type 2 diabetes is often progressive, and worsening of glycemic control over time is likely in many patients. However, some years of improved glycemia may well result in less microvascular disease.”

Both the researchers and commenters called for further studies on the long-term clinical effects of gastric surgery. 

Drug Patent Expirations for the week of May 20, 2012

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
ACTONEL WITH CALCIUM (COPACKAGED)	Warner Chilcott	calcium carbonate; risedronate sodium	6,096,342*PED	May 21, 2012
IMODIUM MULTI-SYMPTOM RELIEF	Mcneil	loperamide hydrochloride; simethicone	5,716,641	May 21, 2012
VIRAMUNE	Boehringer Ingelheim	nevirapine	5,366,972*PED	May 22, 2012
ACTONEL	Warner Chilcott	risedronate sodium	6,096,342*PED	May 22, 2012
VIRAMUNE XR	Boehringer Ingelheim	nevirapine	5,366,972*PED	May 22, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Drug Patent Expirations for the week of May 13, 2012

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
AGGRASTAT	Medicure	tirofiban hydrochloride	5,292,756	May 14, 2012
COMBIVIR	Viiv Hlthcare	lamivudine; zidovudine	5,859,021	May 15, 2012
PLAVIX	Sanofi Aventis Us	clopidogrel bisulfate	4,847,265*PED	May 17, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Drug Patent Expirations for the week of May 6, 2012

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
TRAVATAN Z	Alcon Pharms Ltd	travoprost	6,503,497	May 6, 2012
TRAVATAN Z	Alcon Pharms Ltd	travoprost	6,849,253	May 6, 2012
CRIXIVAN	Merck Sharp Dohme	indinavir sulfate	5,413,999	May 9, 2012
CHILDREN'S ALLEGRA ALLERGY	Sanofi Aventis Us	fexofenadine hydrochloride	6,399,632	May 11, 2012
CHILDREN'S ALLEGRA HIVES	Sanofi Aventis Us	fexofenadine hydrochloride	6,399,632	May 11, 2012
ALLEGRA	Sanofi Aventis Us	fexofenadine hydrochloride	6,187,791	May 11, 2012
CHILDREN'S ALLEGRA ALLERGY	Sanofi Aventis Us	fexofenadine hydrochloride	6,187,791	May 11, 2012
CHILDREN'S ALLEGRA HIVES	Sanofi Aventis Us	fexofenadine hydrochloride	6,187,791	May 11, 2012
ALLEGRA	Sanofi Aventis Us	fexofenadine hydrochloride	6,399,632	May 11, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

GPAT-2012 QUESTION PAPER WITH KEY

OFFICIAL KEY http://www.gpat.in/GPAT2012Keys.pdf
OR
http://pharmawiki.in/wp-content/uploads/2012/05/GPAT-2012-Code-C-101.pdf
OR
http://gdc4gpat.com/download/gpat/01.GPAT-2012_Answer_key.pdf

Drug Patent Expirations for the week of April 29, 2012

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
LIDODERM	Teikoku Pharma Usa	lidocaine	5,411,738	May 2, 2012
LIDODERM	Teikoku Pharma Usa	lidocaine	5,601,838	May 2, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.